（Company Code 7702）

Financial Statements
for the 2nd Quarter of Fiscal Year Ending March 31, 2023
(From Apr. 1, 2022 to Sep. 30, 2022)

Summary of consolidated results
November 4, 2022

© JMS CO.,LTD. All Rights Reserved.

Summary of Financial Results
Consolidated

Increase in sales
Decrease in profit

Net sales
29,975million yen (+1,699 million yen)
Operating profit (44) million yen ((659) million yen)

Sales :

Domestic sales decreased slightly as the impact of the re-expansion of COVID-19 infection
delayed the recovery in demand for consumables. Overseas sales increased due to recovery indemand for Blood bags and AV Fistula Needles, the mainstay products, as well as up in yen
equivalent value due to yen depreciation.

Profit :Despite the effect of increased sales due to growth in overseas sales, income decreased due tothe soaring raw material prices, electricity costs, and ocean freight rates impact, as well as theincrease of labor costs at overseas bases and selling expenses associated with the gradualresumption of sales activities.

Sales by Business Segment
Dialysis :Sales of AV Fistula Needles increased, including to North America, and sales of Dialysis
therapy chairs and Hemodialysis Kits increased in Europe market.

Transfusion : Sales of Blood bags showed signs of recovery in demand and increased mainly in Asia market.

Sales by Region
Asia:

In addition to increased sales of Blood bags, sales of AV fistula needles and Acute Blood
Purification business increased in the China market.

North America:

Sales of AV fistula needles to main customers increased, and sales of Apheresis kits also
recovered.
2© JMS CO.,LTD. All Rights Reserved.

Highlights in Business Results(unit: JPY million)

Apr. - Sep. 2022

Year – over – Year

Apr. - Sep. 2021
Results

Previous Forecast

Results

Net sales

28,275

29,10029,975

1,699

6.0%

Operatingprofit

614

400

(44)

(659)

ー

Ordinary profit

683

400

56

(627)

(91.8)%

Profit attributable toowners of parent

497

250

(68)

(565)

ー

Net sales
28,42628,718Operating profit
27,90028,27529,975

Diff.

Ordinary profit

Profit attributable toowners of parent

1,127

1,046

%

1,060

956

817
614

593

683

637

490

426

497

56

(44)
Apr. - Sep. Apr. - Sep. Apr. - Sep. Apr. - Sep. Apr. - Sep.
2018
2019
2020
2021
2022

Apr. - Sep. Apr. - Sep. Apr. - Sep. Apr. - Sep. Apr. - Sep.
2018
2019
2020
2021
2022

(68)
Apr. - Sep. Apr. - Sep. Apr. - Sep. Apr. - Sep. Apr. - Sep.
2018
2019
2020
2021
2022

© JMS CO.,LTD. All Rights Reserved.

Apr. - Sep. Apr. - Sep. Apr. - Sep. Apr. - Sep. Apr. - Sep.
2018
2019
2020
2021
2022

3

Summary by segment (geographical area)[Japan]Sales of Closed Drug Mixing/Infusion System were strong. Sales of Acute Blood Purification business increased, including to
China market. Profit decreased due to the impact of soaring raw material prices and electricity costs, as well as higher yen
equivalent value of foreign currency-denominated purchase transactions due to yen depreciation increased selling expenses
associated with the gradual increase in sales activities.
[Singapore] Sales of Blood bags increased and sales of Apheresis kits in North America recovered. Despite the impact of soaring raw material
prices, electricity costs, and ocean freight rates, profits increased due to the effect of increased sales and foreign exchange gains.

(unit: JPY million)

Apr. - Sep.
2021
Japan
Singapore※
China
Philippines
Germany
Others※Year-over-Year

Apr. - Sep.
2022

Diff.

%

Sales

20,542

21,361

818

Ordinary profit

587

(89)

(676)

ー

Sales

8,365

10,515

2,150

25.7%

Ordinary profit

26

216

189

715.3%

Sales

1,640

1,878

237

14.5%

Ordinary profit

67

56

(11)

(17.0)%

Sales

1,580

1,668

88

5.6%

Ordinary profit

154

45

(109)

(70.8)%

Sales

1,745

1,870

124

7.1%

Ordinary profit

61

71

10

16.4%

Sales

1,947

2,527

579

29.8%

Ordinary profit

19

(47)

(67)

※Singapore : This segment includes Indonesian subsidiary.
※Others : This segment includes business activity of subsidiaries in Japan, United States, South Korea and Thailand.
© JMS CO.,LTD. All Rights Reserved.

4.0%

ー

4

Sales by Business Segment(unit: JPY million)

Infusion & Nutrition
11,670 11,827

Apr. - Sep. 2021

Dialysis
Apr. - Sep. 2022

8,706

9,345

Despite strong sales of Closed Drug
Mixing/Infusion System, sales slightly increased
due to decrease by Medical Gloves and NutritionSets.

Net sales

CardiovascularTransfusion

2,473

Net sales

Apr. - Sep. 2021

Apr. - Sep. 2022

Apr. - Sep. 2022

Sales of AV Fistula Needles were strong in North
America and other markets, and Dialysis therapy
chairs and Hemodialysis Kits increased in Europe
market.

Net sales

2,780

Apr. - Sep. 2021

4,753

5,268

Sales of Cardiopulmonary Blood Tubing Sets
increased, in addition to increased sales related toAcute Blood Purification business in domestic andChina market.

Apr. - Sep. 2021

Apr. - Sep. 2022

In overseas markets, sales of Blood bags
increased with signs of recovery in demand.

Net sales© JMS CO.,LTD. All Rights Reserved.

5

Sales change by Region (Customer's Location)
In Japan, sales decreased slightly due to the impact of the re-expansion of COVID-19 infection, which slowed the recovery in demand for
consumables.
In overseas markets, Blood bags and AV Fistula Needles increased in Asia, in North America AV Fistula Needles and Apheresis kits increased.

(unit: JPY million)

Year-over-Year

Apr. - Sep.
2021

Apr. - Sep.
2022

Japan

18,915

18,832(82)(0.4)%

62.8%

Asia

3,576

4,530

953

26.7%

15.1%

North America

2,468

3,282

814

33.0%

11.0%

Europe

2,814

2,748

(65)

(2.3)%

9.2%

Others

501

581

79

15.8%

1.9%

Diff.

%

Sales
composition

6© JMS CO.,LTD. All Rights Reserved.

Ordinary profit : Compared with the previous year
[Gross Profit] Decreased due to soaring raw material prices, electricity costs, and ocean freight rates impacts, in addition to increased labor costs[SGA]

at overseas bases.

Increased selling expenses associated with gradual resumption of sales activities and increased transportation expenses due tothe impact of higher prices.

(unit: JPY million)*The underlined figures exclude impact of exchange rate.

Exchange Rate (average during period)
US Dollar(unit: JPY)
Euro

Singapore
DollarApr. - Sep. 2021

109.80129.8281.80

Apr. - Sep. 2022

133.97134.25

96.55© JMS CO.,LTD. All Rights Reserved.

7

Forecast for FYE Mar. 2023
Consolidated business forecast for the fiscal year ending March 31, 2023 released on May 12, 2022 has been revised.

(unit: JPY million)FYE Mar. 2023 Forecast

FYE Mar. 2022
ResultPrevious Forecast

58,16960,00062,000

6.6％

Operating profit

980

1,200

400

(59.2)％

Ordinary profit

1,126

1,200

400

(64.5)％

Profit attributable toowners of parent

826

900

200

(75.8)％Net sales

New Forecast

Year-over-Year%＊Exchange rate for the forecast: 1USD=142yen, 1EUR=138yen, 1SGD=101yen.

Sales：

Demand is on a recovery track, and we continue to increase sales by steadily capturing demand.
Equipment that implemented production adjustments due to difficulties in procuring semiconductors and othercomponents will recover sales in the second half of the year and beyond.

Profit：Further promote cost reductions and absorb the impact of soaring raw material prices and electricity costs.
Continue to review sales prices, ocean freight rates, and other terms and condition of transactions.

8© JMS CO.,LTD. All Rights Reserved.

TOPICS
August 2022
The 7th facility of the Izumo Plant was constructed.

A new 2,000 m2 facility was built to further improve the efficiency of logistics.

September 2022
Announcement of Basic Agreement for Business Alliance withDAIKEN MEDICAL CO., LTD.

Began to consider offering new solutions in anticancer drug treatment (chemotherapy).

9© JMS CO.,LTD. All Rights Reserved.

The Bridge to Good Health Care

The assessment figures described on this report are based on available information at thismoment, including uncertain data. Actual results may be different from the figures.